The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...

Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including ...

A Northwestern Medicine study published in Nature Communications has revealed how HIV can protect infected cells by altering ...

There is currently no cure for HIV, but medications can help people with the disease manage their symptoms. HIV can still develop into AIDS years after infection, however, even with disease management ...

In a groundbreaking discovery, researchers from Florida Atlantic University's Charles E. Schmidt College of Medicine have identified a never-before-seen mechanism that enables the human ...

The FDA granted priority review, with a decision expected by June 19, 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...

HIV hijacks SRRM2 to enlarge nuclear speckles, stabilizing CPSF6 puncta and promoting efficient viral replication.

The efficiency of HIV-1 replication hinges on the dynamic interplay between viral RNA and an array of viral and host proteins. At the core of this process is the dual role of the unspliced viral RNA, ...

Since the HIV epidemic began, the diagnosis of HIV has evolved from a death sentence to a chronic, but manageable condition by starting and staying on treatment. HIV treatment can help people live ...

Nucleoside reverse transcriptase translocation inhibitors (NRTTIs) are a novel class of antiretroviral agents that inhibit HIV replication by targeting the viral reverse transcriptase enzyme and ...

Expert Rev Proteomics. 2008;5(3):507-528. Although it is widely known that HIV-1 initiates a profound global host cell response to infection, it is difficult to trace specific expression and pathway ...